Release date: 2013-02-21
According to the British "Daily Mail" website reported on February 18th, a medical research team in Rome, Italy, announced that they have successfully developed a new type of bionic hand, which can not only complete complex movements, but also pass the patient's nervous system. The connection allows the patient to experience a "realistic" touch.
It is understood that most of the prostheses currently on the market can only play a role in supporting the body, and can not translate the contact between the limb and the outside world as a nerve signal, so it can not bring a sense of touch to the patient. In addition, studies have shown that as many as half of hand amputated patients do not like to use their prostheses because these prostheses make them feel uncomfortable and difficult to integrate with themselves. The new bionic hand can effectively improve this situation. After the electrode is connected to the patient's nervous system, the patient can use his own ideas to control the movement of the bionic hand like ordinary people, and the bionic hand can also correspond. The signal is fed back to the brain.
“The bionic hand that gets the touch is the real hope of the amputee,†said Dr Silvestro Micera, a participant in the study at the Federal Institute of Technology in Lausanne, Switzerland. “Only let them With a real touch, we can truly accept such prostheses. We hope that future bionic hands can be implanted on the patient's arm and even let the user forget about their existence. At the same time, we hope that the new bionic hand can become a technology in the field of prosthetics. Breakthrough, let people with disabilities get a more real touch."
It is reported that the team plans to transplant the bionic hand to an anonymous amputee later this year. "It can bring two or three feelings to the patient at the same time," Dr. Mitchella said. It is able to receive information from the outside world through three fingers, or can feel the movements of the hands and wrists. In addition, we have improved the interface, so the movement and control of the bionic hands will be more refined, and the feeling will be even more lifelike."
Source: Kexun
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com